Belle (@belle22122) header
Belle (@belle22122) profile picture

edrtw | 27 | high sw | 5’7 | 💉

California, USA
Joined September 2021
Photo by Belle (@belle22122)Photo by Belle (@belle22122)Photo by Belle (@belle22122)Photo by Belle (@belle22122)Photo by Belle (@belle22122)Photo by Belle (@belle22122)Photo by Belle (@belle22122)Photo by Belle (@belle22122)Photo by Belle (@belle22122)Photo by Belle (@belle22122)
I hate when some random post goes viral and a bunch of random normal people, minors and bots start following me I been blocking them all day
2
713
Absolutely everything that bothers me of being alive could be 95% better if I wasn’t so fat
684
Belle retweeted
like im so over itttt
41
9,033
153
47,003
261,921
I feel so silly posting these photos but I don’t have anywhere else to post myself and I’m really in love with my hair right now
4
10
931
If only I was like 100lbs lighter
344
I’m not sure how I feel about this. The general idea sounds great in theory but is it really that beneficial to eliminate fat cells? I understand trying to avoid muscle mass loss that happens with glps but that can be prevented by other means. Very interesting still
I went rogue and got my hands on a set of CBL-514 vials, and I’m preparing to design an experiment around this compound. I’ve been digging into the published research, and this one is particularly interesting. Unlike GLP-1 medications, which primarily help reduce energy intake and body weight, CBL-514 is being developed to selectively eliminate fat cells through a process called apoptosis. And the human clinical data are surprisingly promising. Here’s what I’ve learned. 1. What exactly is CBL-514? CBL-514 is an investigational small-molecule injectable developed by Caliway Biopharmaceuticals, a Taiwanese biotechnology company. It is NOT a peptide, GLP-1 agonist, or conventional systemic fat-loss drug. Instead, it targets localized deposits of subcutaneous fat, particularly around the abdomen. Most weight-loss interventions work by reducing the amount of fat stored inside adipocytes. CBL-514 takes a different approach: it is designed to reduce the number of adipocytes themselves. That distinction could become important for long-term fat reduction, although lasting effects haven’t yet been established. 2. What is it made of? This is where things get interesting. A publicly filed 2023 clinical-trial protocol identifies two active ingredients: - Curcumin, a polyphenol found in turmeric. - Trans-resveratrol, a polyphenol found in grapes and certain plants. The historical investigational formulation contained these compounds in a 4:1 curcumin-to-resveratrol ratio by mass. Yes, two compounds commonly associated with nutritional supplements. But this is not equivalent to taking turmeric and resveratrol capsules. The formulation, local delivery, drug exposure, and manufacturing standards matter enormously. And the contents of any independently sourced vial cannot be assumed to match the clinical product. 3. How does it work? The proposed mechanism involves adipocyte apoptosis, or programmed fat-cell death. In preclinical research, the developers describe inhibition of DYRK1B, followed by changes in apoptosis-related pathways, including increased caspase-3 activity and the Bax/Bcl-2 ratio. The proposed sequence is: CBL-514 👉 DYRK1B inhibition 👉 activation of apoptotic signaling 👉 adipocyte death. The idea is to trigger controlled fat-cell death rather than the broader tissue destruction associated with some conventional fat-dissolving injections. Importantly, these mechanistic findings come primarily from nonclinical research. Selectivity and the complete molecular pathway still need stronger confirmation in humans. 4. What do human studies actually show? This is the part that got my attention. 2025 Phase 2 trial, 76 participants. Researchers measured abdominal subcutaneous fat reduction using ultrasound. Eight weeks after the final treatment: - 69.6% of CBL-514 participants achieved at least 150 mL of fat-volume reduction. - 0% of placebo participants reached that threshold. - 60.9% of CBL-514 participants achieved at least 200 mL of reduction. The difference was statistically significant (p < 0.001). 2026 Phase 2b trial, 108 randomized participants. A subsequent trial used clinician and patient assessments alongside MRI. At the 12-week follow-up: - 76.7% of evaluated CBL-514 participants achieved at least a one-grade improvement in abdominal fat appearance. - Only 18.9% of evaluated placebo participants achieved the same result. MRI demonstrated approximately 20.3% reduction in measured abdominal subcutaneous fat volume, corresponding to about 153 mL. These are meaningful signals, especially because imaging supports the appearance-based findings. However, approximately 39% of randomized participants discontinued the study early, including 43% in the treatment group. That substantially limits confidence in the reported response percentages. Promising results? Absolutely. Definitive evidence? Not yet. 5. What about visceral fat? Here’s an unexpected development. In September 2026, researchers presented an exploratory analysis of MRI data from earlier Phase 2 trials. The analysis included 40 participants with later follow-up imaging. At the final assessment: - CBL-514 group: 10.45% reduction in visceral fat volume from baseline. - Placebo group: 11.76% increase. That represents a difference of approximately 22 percentage points. Why is this interesting? Because CBL-514 is administered into subcutaneous tissue, yet the researchers observed changes in visceral fat deeper inside the abdomen. Visceral fat is particularly relevant to metabolic health and cardiometabolic disease risk. But these findings come from a small exploratory subgroup, not a confirmatory trial. We don’t yet know whether the effect is reproducible or translates into meaningful metabolic improvements. 6. Could it work alongside GLP-1 medications? Possibly. And this might eventually become more interesting than localized fat reduction alone. Caliway is investigating combinations with Tirzepatide, Semaglutide and Eloralintide, an investigational amylin-receptor agonist. Preclinical animal studies suggest that combining CBL-514 with some of these treatments may improve weight reduction and potentially limit weight regain after treatment discontinuation. The hypothesis is relatively straightforward: systemic weight-loss medications help reduce stored fat, while eliminating some adipocytes could theoretically change the capacity for subsequent fat accumulation. However, the weight-regain findings are still preclinical. A Phase 2 human combination study with tirzepatide has received FDA investigational clearance, but that is permission to study the combination, not evidence that it works. 7. What do we know about safety? The clinical studies reported mostly temporary injection-site reactions. But those reactions were common. In the 2026 Phase 2b trial: - 73.1% experienced injection-site pain. - 69.2% experienced swelling. - 73.1% experienced itching. - 71.2% experienced bruising. Severe adverse events of any cause were reported in 9.6% of CBL-514 participants versus 3.6% receiving placebo. No treatment-related serious adverse events were identified in that trial, but four treatment participants discontinued because of injection-site pain or hives. The longer-term safety profile remains uncertain. 8. Where does the compound stand today? As of November 2026, CBL-514 has entered Phase 3 development. Two pivotal programs, SUPREME-01 and SUPREME-02, are underway to evaluate abdominal subcutaneous fat reduction. Separately, a related formulation is being investigated for Dercum’s disease, a rare condition associated with painful fatty growths. The company has announced positive Phase 2 pain-reduction results. We are no longer looking at a purely theoretical compound or something supported only by rodent studies. There is human evidence. But CBL-514 is not FDA-approved, and its manufacturer says it has not authorized any commercial sales or third-party distribution. Identity, purity, sterility, and formulation of products sold under that name are therefore major unresolved concerns. 9. What I’m interested in investigating I find CBL-514 intriguing because it represents a fundamentally different approach to adipose tissue modification. The questions that interest me most are: - Can targeted adipocyte apoptosis produce durable changes in localized fat volume? - Does the observed reduction persist after treatment ends? - Is the reported visceral-fat effect reproducible? - Could this mechanism eventually complement systemic weight-loss medications? - How much of the promising early evidence will survive larger, longer clinical trials? I’m working on an experimental design and will document what can actually be established, including the limitations and uncertainties. I’m particularly interested in separating objective measurements from subjective appearance changes. For now, the clinical evidence supports further investigation, not conclusions about safety or efficacy outside controlled trials. CBL-514 is one of the more unusual fat-reduction candidates I’ve researched. It has a plausible proposed mechanism, encouraging Phase 2 results, and an expanding clinical program. But the gaps between a promising investigational drug, a verified clinical-grade product, and a safe treatment are enormous. I’ll share more as the research progresses. Not medical advice or a recommendation to use an unapproved injectable.
417
Belle retweeted
Sometimes in your 20s or 30s you’ll get the opportunity to rebuild your life after a negative & traumatic loop. Heal from what broke you, live in your own space. Reconnect with your discipline and learn to love yourself again. It’s very important that you see that journey through
44
2,435
130
14,623
242,058
My perception of time is so off. Two months feels like absolutely nothing but 60 days? Omg 60 days is soooo much
4
314
Belle retweeted
feeling suicidal and knowing very well you can't take your own life is such a pathetic feeling.
149
15,142
348
82,156
1,699,973
22
3,542
192
16,027
142,057
encontrar una obsesion cuando estas en pleno episodio depresivo
254
40,569
3,045
191,415
1,398,436
My love life is defined by this stupid song
1
1,025
And this one
1
106
And this one
101